Potential targets for pancreatic cancer immunotherapeutics

Lindzy F. Dodson, William G. Hawkins, Peter Goedegebuure

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations


Pancreatic adenocarcinoma is the fourth leading cause of cancer death with an overall 5-year survival of less than 5%. As there is ample evidence that pancreatic adenocarcinomas elicit antitumor immune responses, identification of pancreatic cancer-associated antigens has spurred the development of vaccination-based strategies for treatment. While promising results have been observed in animal tumor models, most clinical studies have found only limited success. As most trials were performed in patients with advanced pancreatic cancer, the contribution of immune suppressor mechanisms should be taken into account. In this article, we detail recent work in tumor antigen vaccination and the recently identified mechanisms of immune suppression in pancreatic cancer. We offer our perspective on how to increase the clinical efficacy of vaccines for pancreatic cancer.

Original languageEnglish
Pages (from-to)517-537
Number of pages21
Issue number4
StatePublished - Apr 2011


  • MDSC
  • T cell
  • Treg
  • chimeric antigen receptor
  • immune suppression
  • immune therapy
  • pancreatic cancer
  • vaccine


Dive into the research topics of 'Potential targets for pancreatic cancer immunotherapeutics'. Together they form a unique fingerprint.

Cite this